During the last weeks, a team of Ascenion’s industry liaison and technology mangers has been on the road to foster industry relations and market the company’s portfolio of IP assets.
In October, they joined a delegation of European biotech clusters on their trip to Asia: first to Osaka, then to the BioJapan conference in Yokohama. ‘Personal…
Most of you will have heard about the approval of BLINCYTO® and VONVENDI – both drugs based in part on our partners’ intellectual property. These are the big moments in technology transfer: when the benefits to patients become tangible. However these wouldn’t be possible without the many small steps and minor successes along the way that often…
As a long-term partner and supporter of BioFIT Ascenion cordially invites you to join the event. BioFIT is a premier partnering platform in Europe for technology transfer, academia-industry collaborations and for licensing early-stage life-science innovations. It brings together over 1,300 decision makers in the sector – technology transfer…
Technology transfer professionals from all over Europe have the unique opportunity to visit one of the world's largest and most respected centres for scientific research: the European Organization for Nuclear Research (CERN). Participants will be able to network with CERN knowledge and technology transfer experts and to learn how CERN…
19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), has mediated an agreement with Heidelberg Pharma, a subsidiary of WILEX AG. It provides the company with an exclusive option to a set of humanized anti-BCMA antibodies generated at the…
Marta Catarino, Director of TecMinho, Portugal, is the new president of the pan-European association for technology transfer (TT) professionals, ASTP-Proton. Together with the ASTP-Proton team, and with the active support of its members, she will continue to drive the transformation of the association initiated by former presidents Sara…
Around 40 commercially attractive, licensable technologies that were presented at this year’s BioVaria are now available online – including videos of the corresponding 10-min pitches. The technologies cover potential therapeutics and diagnostics, as well as platform technologies, and originate from 32 academic institutions and universities in…
For the first time, a German team has won the world’s biggest life-science start-up competition. Captain T Cell, founded by Dr Felix Lorenz and several colleagues at the MDC, beat 400 international start-ups to win prize money totalling GBP 100,000. The team will use the funds to further develop their innovative approach to cancer immunotherapy.…
BioVaria Spin-off Awards go to Charité spin-off and Braingineering Technologies
19 May 2016, Munich, Germany – Dealmakers and investors from the international biopharmaceutical industry gathered in Munich on 17 May 2016 to meet some of the most innovative minds from academic life-science research in Europe. Their aim: to initiate partnerships for…
With Ascenion‘s help, the MDC established a unique translational centre in 2016 - the ‚Max-Delbrück Center Cell Engineering Lab‘ (MD-CEL). Its goal is to advance a completely new concept of cell-based gene therapy for cancer. Precisely because the approach is so new, there are many challenges to be overcome on the way to clinical application. This…
As a member of the TechnologieAllianz – the German association for knowledge and technology transfer – Ascenion warmly invites you to attend the TechnologieAllianz conference to be held on 31 May 2016 in Frankfurt under the patronage of the German Minister for Economic Affairs, Sigmar Gabriel.
Look forward to discussions with the following…
A ground-breaking approach to the therapy of HIV infection has been published in the current issue of Nature Biotechnology: a designer recombinase that is selectively activated in HIV-infected cells and then specifically excises the virus from the cell genome without damaging the host cell. In contrast to existing treatment strategies, this…
BioVaria is designed for dealmakers and investors from the global life-science sector responsible for identifying, licensing or funding break-through innovations. In just one interactive day it showcases around 50 licensable life-science technologies originating from publicly funded research as well as some of Europe’s most promising…
WIPANO (Wissenstransfer durch Patente und Normen: knowledge transfer via patents and standards) is the successor to SIGNO, and has been running since January. According to the new guidelines, universities, non-university research facilities and small to medium-sized companies can apply for funding in three areas:
Evaluation, patenting and…
BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry. Over 50 licensable life-science projects from 50 academic research institutes in 10 European countries were presented at the last BioVaria, together with seven selected…
The German Bioregions will be awarding their Innovation Prize for the ninth time. They are looking for application-oriented patents in the fields of biotechnology or medical technology with particularly high commercial potential. Eligible are scientists who:
work at a university or a public research institute,hold or have submitted a patent with…
